| 纯度 | >85%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | MAP2K1 |
| Uniprot No | P31938 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-393aa |
| 氨基酸序列 | PKKKPTPIQ LNPAPDGSAV NGTSSAETNL EALQKKLEEL ELDEQQRKRL EAFLTQKQKV GELKDDDFEK ISELGAGNGG VVFKVSHKPS GLVMARKLIH LEIKPAIRNQ IIRELQVLHE CNSPYIVGFY GAFYSDGEIS ICMEHMDGGS LDQVLKKAGR IPEQILGKVS IAVIKGLTYL REKHKIMHRD VKPSNILVNS RGEIKLCDFG VSGQLIDSMA NSFVGTRSYM SPERLQGTHY SVQSDIWSMG LSLVEMAVGR YPIPPPDAKE LELLFGCHVE GDAAETPPRP RTPGRPLSSY GMDSRPPMAI FELLDYIVNE PPPKLPSGVF SLEFQDFVNK CLIKNPAERA DLKQLMVHAF IKRSDAEEVD FAGWLCSTIG LNQPSTPTHA ASI |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structure of the MAPK scaffold, MP1. bound to its partner, p14: A complex with critical role in endosomal map kinase signaling"**
*作者：Jia, Z., Barford, D., et al.*
摘要：该研究解析了包含MAP2K1(MEK1)信号复合物的结构，探讨了重组MEK1在MAPK信号通路中的作用机制，阐明了其与下游效应分子p14的相互作用对胞内信号转导的影响。
2. **"Expression and purification of active recombinant MEK1 from Escherichia coli"**
*作者：Crews, C.M., Erikson, R.L.*
摘要：报道了通过大肠杆菌表达系统高效制备活性重组MAP2K1(MEK1)的方法，优化了纯化步骤，并验证了重组蛋白的激酶活性及其在体外磷酸化ERK的能力。
3. **"Crystal structure of human MEK1 kinase domain in complex with allosteric inhibitor"**
*作者：Ohren, J.F., et al.*
摘要：利用重组表达的MEK1激酶结构域解析其与变构抑制剂的复合物晶体结构，揭示了MEK1的ATP结合位点构象变化，为靶向MEK1的药物设计提供了结构基础。
4. **"Functional analysis of MEK1 mutations in cardio-facio-cutaneous syndrome"**
*作者：Rodriguez-Viciana, P., et al.*
摘要：通过重组MEK1蛋白研究其突变体(如P124L)的功能异常，发现突变导致ERK信号通路过度激活，与遗传性疾病CFC综合征的发病机制相关。
MAP2K1. also known as MEK1. is a dual-specificity kinase within the MAPK/ERK signaling pathway, playing a central role in regulating cellular processes such as proliferation, differentiation, and apoptosis. As a critical intermediary between RAF kinases and ERK1/2. MAP2K1 activates ERK through phosphorylation, transmitting extracellular signals (e.g., growth factors, cytokines) to nuclear transcription factors. Dysregulation of MAP2K1 is frequently implicated in cancers, particularly those with RAS/RAF mutations, making it a key therapeutic target.
Recombinant MAP2K1 proteins are engineered using expression systems like *E. coli* or mammalian cells to produce functional, purified kinase for research and drug discovery. These proteins typically retain catalytic activity and structural features, including conserved kinase domains (e.g., ATP-binding site) and regulatory motifs. Tagged variants (e.g., His-tag, GST-tag) facilitate purification and detection. Recombinant MAP2K1 enables *in vitro* studies of kinase activation mechanisms, substrate interactions, and inhibitor screening. MEK inhibitors like trametinib, derived from such research, are clinically used to treat BRAF-mutant cancers. Additionally, recombinant MAP2K1 supports structural biology (e.g., crystallography) to elucidate binding interfaces and design selective drugs. Its production requires optimization to maintain solubility and post-translational modification fidelity, ensuring relevance to physiological conditions.
×
